<DOC>
	<DOCNO>NCT00127452</DOCNO>
	<brief_summary>The Alpha Omega Trial randomize , placebo-controlled , double-blind dietary intervention study 4837 postmyocardial infarction patient Netherlands examine whether incidence cardiovascular diseases 40 month follow-up prevent low dos omega-3 polyunsaturated fatty acid . The key objective : - examine effect low-dose supplementation ( 400 mg/day ) eicosapentaenoic acid docosahexaenoic acid incidence cardiovascular disease ; - examine effect low-dose supplementation ( 2 g/day ) alpha-linolenic acid incidence cardiovascular disease .</brief_summary>
	<brief_title>Alpha Omega Trial : Study Omega-3 Fatty Acids Coronary Mortality</brief_title>
	<detailed_description>Whether dietary omega-3 ( n-3 ) polyunsaturated fatty acid causally relate risk cardiovascular disease ( CVD ) major , unresolved question preventive cardiology . Essential n-3 fatty acid eicosapentaenoic acid ( EPA ; C20:5 , n-3 ) docosahexaenoic acid ( DHA ; C22:6 , n-3 ) one hand , parent compound alpha-linolenic acid ( ALA ; C18:3 , n-3 ) hand . The intake n-3 fatty acid recommend level Western population . The Alpha Omega Trial randomize , double-blind , placebo-controlled study effect low-dose supplementation ALA EPA-DHA CVD . A total 4837 Dutch men woman age 60-80 year myocardial infarction past 10 year randomly allocate 2 g/d ALA , 400 mg/d EPA-DHA , 2 g/d ALA + 400 mg/d EPA-DHA , placebo , 40 month . Increased intake n-3 fatty acid achieve daily use 20 g margarine bread . Margarines treatment group similar taste appearance . The primary outcome trial 'major cardiovascular event ' , comprise incident CVD cardiac intervention ( PCI CABG ) follow-up . Secondary endpoint incident CVD , fatal CVD , fatal CHD all-causes mortality . Complete follow-up vital status achieve . Cause-specific mortality cod independent Endpoint Adjudication Committee . Physical examination , blood sample data collection diet lifestyle perform subject baseline , 810 randomly select subject 20 month intervention , 58 % cohort end follow-up . Cardiovascular health , serious adverse event , lifestyle , fish intake margarine use monitor subject yearly telephone interview . Compliance continuously monitor registration margarine tub . An objective biomarker compliance ( i.e . plasma n-3 fatty acid ) obtain randomly select subject baseline 20 40 month intervention . The Alpha Omega Trial could provide sound scientific basis dietary recommendation intake ALA EPA-DHA , order reduce burden cardiovascular disease .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Inclusion criterion : Men woman Aged 60 80 Verified clinically diagnose myocardial infarction 10 randomization Written inform consent Exclusion criterion : Living nursing home institution Participation another scientific study Habitual margarine intake &lt; 10 g per day Habitual fish intake &gt; 150 g per day Habitual alcohol intake &gt; 6 drink per day Use fish oil capsule supplement contain omega3 fatty acid Presence cancer &lt; 1 life expectancy Cognitive impairment , indicate Mini Mental State Examination ( score &lt; = 21 ) Unintended weight loss &gt; 5 kg past year Lack facility cool margarine storage home Inability unwillingness comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>alpha-linolenic acid</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>coronary patient</keyword>
	<keyword>DHA</keyword>
	<keyword>dietary intervention</keyword>
	<keyword>dietary supplementation</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>eicosapentaenoic acid</keyword>
	<keyword>EPA</keyword>
	<keyword>fish oil</keyword>
	<keyword>fish fatty acid</keyword>
	<keyword>human subject</keyword>
	<keyword>ischaemic heart disease</keyword>
	<keyword>margarine</keyword>
	<keyword>marine fatty acid</keyword>
	<keyword>mortality</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>n-3 fatty acid</keyword>
	<keyword>n-3 polyunsaturated fatty acid</keyword>
	<keyword>n-3 PUFA</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>omega-3 polyunsaturated fatty acid</keyword>
	<keyword>prevention</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>secondary prevention</keyword>
</DOC>